准用N-乙-银胺-结合小干扰RNA向 ангиотензиноген,降低血压
Dien Ye1, Edwyn O Cruz-López1, Ho-Chou Tu2
1Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands (D.Y., E.O.C.-L., A.H.J.D.).
Arteriosclerosis, thrombosis, and vascular biology
|October 19, 2023
概括
用小干扰RNA向肝血管酶原 (AGT) 提供了一种新的方法,通过阻断宁-血管酶系统 (RAS) 来控制高血压. 这种方法可以克服当前治疗方法的局限性,改善患者的坚持.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 目前针对氨酸-血管新生系统 (RAS) 的抗高血压疗法可能受到患者不良坚持和RAS逃逸现象的限制.
- RAS逃逸现象的特点是补偿性蛋白升高,这可能会降低RAS阻塞的有效性.
研究的目的:
- 审查目前针对使用小干扰RNA (siRNA) 作为一种新型抗高血压策略的肝血管酶激素 (AGT) 的研究结果.
- 为了比较AGT siRNA与传统的RAS阻断方法 (ACE抑制剂,AT1受体对抗剂) 和反感性寡核酸.
- 讨论AGTsiRNA对未来高血压管理的影响,包括不经常服用的可能性.
主要方法:
- 在高血压模型中对AGTsiRNA进行临床前研究的综述.
- 对抗经典RAS阻断的AGTsiRNA疗效和通过反感性寡核酸抑制AGT抑制的比较.
- 对AGT siRNA.第一个在人体上的研究数据的分析.
主要成果:
- 用siRNA准肝脏AGTmRNA降解提供了一种强有力的和特定的方法来阻止RAS.
- AGT siRNA通过防止其源处产生血管新生素来规避RAS逃逸现象.
- 临床前数据和早期人类研究表明AGT siRNA是高血压治疗的有前途的治疗方法.
结论:
- 通过siRNA抑制肝脏AGT是一种有前途的,可能改善高血压管理的坚持策略.
- AGT siRNA提供了传统RAS封锁的替代方案,解决了像RAS逃逸现象这样的局限性.
- 未来的高血压治疗可能涉及不频繁的AGT siRNA疗法,提高患者的遵从性.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
650
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
650
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
752
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
752
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
674
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
674
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
02:30siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
02:15Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K